tris buffer (Jena Bioscience)

Jena Bioscience tris buffer
Tris Buffer, supplied by Jena Bioscience, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tris buffer/product/Jena Bioscience
Average 92 stars, based on 1 article reviews

tris buffer - by Bioz Stars, 2026-06

92/100 stars

Buy from Supplier

crispr cas12a reaction solution (New England Biolabs)

New England Biolabs crispr cas12a reaction solution
Crispr Cas12a Reaction Solution, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crispr cas12a reaction solution/product/New England Biolabs
Average 99 stars, based on 1 article reviews

crispr cas12a reaction solution - by Bioz Stars, 2026-06

99/100 stars

Buy from Supplier

anti pax8 mouse antibody (Cell Signaling Technology Inc)

Cell Signaling Technology Inc anti pax8 mouse antibody
$Three-step proteomic approach identifies putative <t>PAX8-interacting</t> partners. (a) Schematic of the workflow for the PAX8-interacting partner’s identification. (b) Representative examples of endogenous PAX8 immunoprecipitation silver-stained gel and immunoblot from fallopian tube secretory cells (FT) and ovarian carcinoma cells (OV). IMR90 cells, which are PAX8 negative, were used as negative control (C). (c) Immunoblot of size-exclusion fractions showing the presence of PAX8 at 600 kDa size range. PAX8 immunoprecipitates and gel-filtration fractions were sent for mass spectrometry analysis. (d) Volcano plot of identified putative PAX8-interacting partners. (e) Confirmation of PAX8 and SOX17 interaction by co-immunoprecipitation experiments from FTSEC and HGSOC cell lines. (f) PAX8 and SOX17 immunoblots of size exclusion fractions demonstrate co-elution at 600 kDa size range fractions.$
Anti Pax8 Mouse Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pax8 mouse antibody/product/Cell Signaling Technology Inc
Average 91 stars, based on 1 article reviews

anti pax8 mouse antibody - by Bioz Stars, 2026-06

91/100 stars

Buy from Supplier

blocking buffer (Thermo Fisher)

Thermo Fisher blocking buffer
$Three-step proteomic approach identifies putative <t>PAX8-interacting</t> partners. (a) Schematic of the workflow for the PAX8-interacting partner’s identification. (b) Representative examples of endogenous PAX8 immunoprecipitation silver-stained gel and immunoblot from fallopian tube secretory cells (FT) and ovarian carcinoma cells (OV). IMR90 cells, which are PAX8 negative, were used as negative control (C). (c) Immunoblot of size-exclusion fractions showing the presence of PAX8 at 600 kDa size range. PAX8 immunoprecipitates and gel-filtration fractions were sent for mass spectrometry analysis. (d) Volcano plot of identified putative PAX8-interacting partners. (e) Confirmation of PAX8 and SOX17 interaction by co-immunoprecipitation experiments from FTSEC and HGSOC cell lines. (f) PAX8 and SOX17 immunoblots of size exclusion fractions demonstrate co-elution at 600 kDa size range fractions.$
Blocking Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blocking buffer/product/Thermo Fisher
Average 98 stars, based on 1 article reviews

blocking buffer - by Bioz Stars, 2026-06

98/100 stars

Buy from Supplier

array buffer 1 (R&D Systems)

R&D Systems array buffer 1
$Three-step proteomic approach identifies putative <t>PAX8-interacting</t> partners. (a) Schematic of the workflow for the PAX8-interacting partner’s identification. (b) Representative examples of endogenous PAX8 immunoprecipitation silver-stained gel and immunoblot from fallopian tube secretory cells (FT) and ovarian carcinoma cells (OV). IMR90 cells, which are PAX8 negative, were used as negative control (C). (c) Immunoblot of size-exclusion fractions showing the presence of PAX8 at 600 kDa size range. PAX8 immunoprecipitates and gel-filtration fractions were sent for mass spectrometry analysis. (d) Volcano plot of identified putative PAX8-interacting partners. (e) Confirmation of PAX8 and SOX17 interaction by co-immunoprecipitation experiments from FTSEC and HGSOC cell lines. (f) PAX8 and SOX17 immunoblots of size exclusion fractions demonstrate co-elution at 600 kDa size range fractions.$
Array Buffer 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/array buffer 1/product/R&D Systems
Average 93 stars, based on 1 article reviews

array buffer 1 - by Bioz Stars, 2026-06

93/100 stars

Buy from Supplier

lysis buffer provided by the human apoptosis array kit r d systems (R&D Systems)

R&D Systems lysis buffer provided by the human apoptosis array kit r d systems
$Three-step proteomic approach identifies putative <t>PAX8-interacting</t> partners. (a) Schematic of the workflow for the PAX8-interacting partner’s identification. (b) Representative examples of endogenous PAX8 immunoprecipitation silver-stained gel and immunoblot from fallopian tube secretory cells (FT) and ovarian carcinoma cells (OV). IMR90 cells, which are PAX8 negative, were used as negative control (C). (c) Immunoblot of size-exclusion fractions showing the presence of PAX8 at 600 kDa size range. PAX8 immunoprecipitates and gel-filtration fractions were sent for mass spectrometry analysis. (d) Volcano plot of identified putative PAX8-interacting partners. (e) Confirmation of PAX8 and SOX17 interaction by co-immunoprecipitation experiments from FTSEC and HGSOC cell lines. (f) PAX8 and SOX17 immunoblots of size exclusion fractions demonstrate co-elution at 600 kDa size range fractions.$
Lysis Buffer Provided By The Human Apoptosis Array Kit R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lysis buffer provided by the human apoptosis array kit r d systems/product/R&D Systems
Average 91 stars, based on 1 article reviews

lysis buffer provided by the human apoptosis array kit r d systems - by Bioz Stars, 2026-06

91/100 stars

Buy from Supplier

3dna array 900 (Genisphere llc)

Genisphere llc 3dna array 900
$Three-step proteomic approach identifies putative <t>PAX8-interacting</t> partners. (a) Schematic of the workflow for the PAX8-interacting partner’s identification. (b) Representative examples of endogenous PAX8 immunoprecipitation silver-stained gel and immunoblot from fallopian tube secretory cells (FT) and ovarian carcinoma cells (OV). IMR90 cells, which are PAX8 negative, were used as negative control (C). (c) Immunoblot of size-exclusion fractions showing the presence of PAX8 at 600 kDa size range. PAX8 immunoprecipitates and gel-filtration fractions were sent for mass spectrometry analysis. (d) Volcano plot of identified putative PAX8-interacting partners. (e) Confirmation of PAX8 and SOX17 interaction by co-immunoprecipitation experiments from FTSEC and HGSOC cell lines. (f) PAX8 and SOX17 immunoblots of size exclusion fractions demonstrate co-elution at 600 kDa size range fractions.$
3dna Array 900, supplied by Genisphere llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3dna array 900/product/Genisphere llc
Average 90 stars, based on 1 article reviews

3dna array 900 - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

Image Search Results

$Three-step proteomic approach identifies putative PAX8-interacting partners. (a) Schematic of the workflow for the PAX8-interacting partner’s identification. (b) Representative examples of endogenous PAX8 immunoprecipitation silver-stained gel and immunoblot from fallopian tube secretory cells (FT) and ovarian carcinoma cells (OV). IMR90 cells, which are PAX8 negative, were used as negative control (C). (c) Immunoblot of size-exclusion fractions showing the presence of PAX8 at 600 kDa size range. PAX8 immunoprecipitates and gel-filtration fractions were sent for mass spectrometry analysis. (d) Volcano plot of identified putative PAX8-interacting partners. (e) Confirmation of PAX8 and SOX17 interaction by co-immunoprecipitation experiments from FTSEC and HGSOC cell lines. (f) PAX8 and SOX17 immunoblots of size exclusion fractions demonstrate co-elution at 600 kDa size range fractions.$

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: Three-step proteomic approach identifies putative PAX8-interacting partners. (a) Schematic of the workflow for the PAX8-interacting partner’s identification. (b) Representative examples of endogenous PAX8 immunoprecipitation silver-stained gel and immunoblot from fallopian tube secretory cells (FT) and ovarian carcinoma cells (OV). IMR90 cells, which are PAX8 negative, were used as negative control (C). (c) Immunoblot of size-exclusion fractions showing the presence of PAX8 at 600 kDa size range. PAX8 immunoprecipitates and gel-filtration fractions were sent for mass spectrometry analysis. (d) Volcano plot of identified putative PAX8-interacting partners. (e) Confirmation of PAX8 and SOX17 interaction by co-immunoprecipitation experiments from FTSEC and HGSOC cell lines. (f) PAX8 and SOX17 immunoblots of size exclusion fractions demonstrate co-elution at 600 kDa size range fractions.

Article Snippet: PLA signals were determined employing Duolink Probes Anti-Mouse MINUS (Sigma-Aldrich: DUO92004) and Anti-Rabbit PLUS (Sigma-Aldrich: DUO92002) as manufacturer’s recommended protocol following overnight incubation with anti-PAX8 mouse antibody 1:250 (Novus: NBP2-29903) and anti-SOX17 rabbit antibody 1:250 (Cell Signaling: 81778S) at 4 °C.

Techniques: Immunoprecipitation, Staining, Western Blot, Negative Control, Filtration, Mass Spectrometry, Co-Elution Assay

PAX8 and SOX17 have a strong correlation and dependency on ovarian cancer. (a) TCGA ovarian cancer Pearson correlation of PAX8 with the newly identified PAX8-interacting partners. (b) SOX17 has the strongest correlation with PAX8 in ovarian cancer. (c) Ovarian carcinoma cells PAX8 dependency. (d) Ovarian carcinoma cells SOX17 dependency and (e) Ovarian carcinoma cells PAX8-SOX17 co-dependency.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8 and SOX17 have a strong correlation and dependency on ovarian cancer. (a) TCGA ovarian cancer Pearson correlation of PAX8 with the newly identified PAX8-interacting partners. (b) SOX17 has the strongest correlation with PAX8 in ovarian cancer. (c) Ovarian carcinoma cells PAX8 dependency. (d) Ovarian carcinoma cells SOX17 dependency and (e) Ovarian carcinoma cells PAX8-SOX17 co-dependency.

Techniques:

PAX8 physically interacts with SOX17 in the fallopian tubes and in ovarian cancer. (a) Immunohistochemistry showing nuclear co-expression of PAX8 and SOX17 in FTSEC and HGSOC cells. 5 normal samples and 5 ovarian cancer patients were analyzed and one representative case of each is shown. (b) Immunofluorescence showing co-localization of PAX8 and SOX17 in benign cells (FT194, FT246, and FT282) and in malignant cells (OVCAR4, KURAMOCHI, and OVSAHO). (c) Proximity ligation assay signals in secretory cells (FT194, FT246, and FT282) and in carcinoma cells (OVCAR4, KURAMOCHI, and OVSAHO) are shown in red. The nuclei are stained with DAPI (blue). The nuclei were acquired in one z-plane with 60X magnification. (d) In situ proximity ligation assay signals in normal fallopian tube sections and high-grade serous ovarian cancer samples shown in brown and the nuclei in orange. The nuclei were acquired in one z-plane with 40x magnification. *Number of PLA signals (PAX8-SOX17 interactions) was determined by counting 100 nuclei per sample (Supplemental information 2).

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8 physically interacts with SOX17 in the fallopian tubes and in ovarian cancer. (a) Immunohistochemistry showing nuclear co-expression of PAX8 and SOX17 in FTSEC and HGSOC cells. 5 normal samples and 5 ovarian cancer patients were analyzed and one representative case of each is shown. (b) Immunofluorescence showing co-localization of PAX8 and SOX17 in benign cells (FT194, FT246, and FT282) and in malignant cells (OVCAR4, KURAMOCHI, and OVSAHO). (c) Proximity ligation assay signals in secretory cells (FT194, FT246, and FT282) and in carcinoma cells (OVCAR4, KURAMOCHI, and OVSAHO) are shown in red. The nuclei are stained with DAPI (blue). The nuclei were acquired in one z-plane with 60X magnification. (d) In situ proximity ligation assay signals in normal fallopian tube sections and high-grade serous ovarian cancer samples shown in brown and the nuclei in orange. The nuclei were acquired in one z-plane with 40x magnification. *Number of PLA signals (PAX8-SOX17 interactions) was determined by counting 100 nuclei per sample (Supplemental information 2).

Techniques: Immunohistochemistry, Expressing, Immunofluorescence, Proximity Ligation Assay, Staining, In Situ

Overexpression of PAX8 and SOX17 in ovarian carcinoma cases. (a) Higher expression of PAX8 in ovarian cancer samples. (b) Differential expression of SOX17 in ovarian cancer samples. (c) Most of the TCGA ovarian cancer samples have high PAX8 and SOX17 co-expression. (d) Higher number of PAX8-SOX17 interactions on ovarian cancer cell lines.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: Overexpression of PAX8 and SOX17 in ovarian carcinoma cases. (a) Higher expression of PAX8 in ovarian cancer samples. (b) Differential expression of SOX17 in ovarian cancer samples. (c) Most of the TCGA ovarian cancer samples have high PAX8 and SOX17 co-expression. (d) Higher number of PAX8-SOX17 interactions on ovarian cancer cell lines.

Techniques: Over Expression, Expressing

PAX8 and SOX17 are transcription co-regulators. (a-b) Immunoblot analyses following knockdown of PAX8 or SOX17 in FTSEC (FT194, FT246, and FT282) and in HGSOC (OVCAR4, KURAMOCHI, and OVSAHO) cells showing SOX17 expression dependency on PAX8 regulation. (c-d) Real-time PCR analysis following of PAX8 or SOX17 in FTSEC (FT194, FT246, and FT282) and in HGSOC (OVCAR4, KURAMOCHI, and OVSAHO) cells depicting the transcriptional co-regulation of SOX17 by PAX8. (e-f) Luciferase reporter assay using reporter with 5X PAX8-recognition sequence.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8 and SOX17 are transcription co-regulators. (a-b) Immunoblot analyses following knockdown of PAX8 or SOX17 in FTSEC (FT194, FT246, and FT282) and in HGSOC (OVCAR4, KURAMOCHI, and OVSAHO) cells showing SOX17 expression dependency on PAX8 regulation. (c-d) Real-time PCR analysis following of PAX8 or SOX17 in FTSEC (FT194, FT246, and FT282) and in HGSOC (OVCAR4, KURAMOCHI, and OVSAHO) cells depicting the transcriptional co-regulation of SOX17 by PAX8. (e-f) Luciferase reporter assay using reporter with 5X PAX8-recognition sequence.

Techniques: Western Blot, Expressing, Real-time Polymerase Chain Reaction, Luciferase, Reporter Assay, Sequencing

PAX8-SOX17 expression co-regulation. (a-b) Immunoblot of four deconvoluted siPAX8 and four deconvoluted siSOX17 knockdowns on FTSEC and HGSOC cell lines. (c-d) PAX8 and SOX17 protein levels after knockdowns with four pooled siPAX8, four pooled siSOX17 or then all combined by reverse-phase protein array.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8-SOX17 expression co-regulation. (a-b) Immunoblot of four deconvoluted siPAX8 and four deconvoluted siSOX17 knockdowns on FTSEC and HGSOC cell lines. (c-d) PAX8 and SOX17 protein levels after knockdowns with four pooled siPAX8, four pooled siSOX17 or then all combined by reverse-phase protein array.

Techniques: Expressing, Western Blot, Protein Array

PAX8 and SOX17 regulate a common set of genes. (a) RNA-seq unsupervised clustering of PAX8, SOX17, and commonly regulated target genes. Profiles obtained with OVCAR4 after 72 hr knockdowns; fold change >1; P < 0.05. (b) Venn diagram representing number of genes up-regulated under each condition. (c) Ontology analysis of the PAX8-SOX17 commonly up-regulated genes. (d) RPPA unsupervised clustering of PAX8-SOX17 commonly regulated proteins. (e) Top-ranked PAX8-SOX17 commonly regulated proteins. (f) Immunoblot showing SERPINE1 up-regulation after PAX8 or SOX17 knockdown. (g) Real-time PCR showing SERPINE1 up-regulation after PAX8 or SOX17 knockdown.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8 and SOX17 regulate a common set of genes. (a) RNA-seq unsupervised clustering of PAX8, SOX17, and commonly regulated target genes. Profiles obtained with OVCAR4 after 72 hr knockdowns; fold change >1; P < 0.05. (b) Venn diagram representing number of genes up-regulated under each condition. (c) Ontology analysis of the PAX8-SOX17 commonly up-regulated genes. (d) RPPA unsupervised clustering of PAX8-SOX17 commonly regulated proteins. (e) Top-ranked PAX8-SOX17 commonly regulated proteins. (f) Immunoblot showing SERPINE1 up-regulation after PAX8 or SOX17 knockdown. (g) Real-time PCR showing SERPINE1 up-regulation after PAX8 or SOX17 knockdown.

Techniques: RNA Sequencing Assay, Western Blot, Real-time Polymerase Chain Reaction

PAX8-SOX17 tightly suppresses SERPINE1 expression. (a) RNA-seq analysis depicting SERPINE1 gene up-regulation after PAX8, SOX17 or DUAL knockdown. (b) SERPINE1 average expression after PAX8, SOX17 or DUAL knockdown. (c) RPPA ontology analysis corroborating enrichment of angiogenesis and VEGF pathways. (d) SERPINE1 relative protein levels in different FTSEC lines and HGSOC lines, depicting suppression of SERPINE1 during malignant transformation. (e) Immunoblot of different benign and malignant cell lines showing drastically reduction of SERPINE1 levels in cell lines with increased SOX17 expression.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8-SOX17 tightly suppresses SERPINE1 expression. (a) RNA-seq analysis depicting SERPINE1 gene up-regulation after PAX8, SOX17 or DUAL knockdown. (b) SERPINE1 average expression after PAX8, SOX17 or DUAL knockdown. (c) RPPA ontology analysis corroborating enrichment of angiogenesis and VEGF pathways. (d) SERPINE1 relative protein levels in different FTSEC lines and HGSOC lines, depicting suppression of SERPINE1 during malignant transformation. (e) Immunoblot of different benign and malignant cell lines showing drastically reduction of SERPINE1 levels in cell lines with increased SOX17 expression.

Techniques: Expressing, RNA Sequencing Assay, Transformation Assay, Western Blot

PAX8 and SOX17 regulate the secretion of angiogenesis mediators. (a) Human angiogenesis array of conditioned media from FTSEC and HGSOC cells following PAX8 or SOX17 knockdown. (b) Effect of PAX8 knockdown on specific analytes was produced by quantifying the array membrane spots intensity. (c) ELISA for quantification of secreted SERPINE1 in the FTSEC- and HGSOC-conditioned media. (d) ELISA for the quantitation of secreted VEGF in the FTSEC and HGSOC conditioned media. (e) ELISA showing SERPINE1 secreted by FTSEC and HGSOC. (f) ELISA experiments showing the effects of PAX8 or SOX17 knockdown on levels of SERPINE1 in HGSOC.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8 and SOX17 regulate the secretion of angiogenesis mediators. (a) Human angiogenesis array of conditioned media from FTSEC and HGSOC cells following PAX8 or SOX17 knockdown. (b) Effect of PAX8 knockdown on specific analytes was produced by quantifying the array membrane spots intensity. (c) ELISA for quantification of secreted SERPINE1 in the FTSEC- and HGSOC-conditioned media. (d) ELISA for the quantitation of secreted VEGF in the FTSEC and HGSOC conditioned media. (e) ELISA showing SERPINE1 secreted by FTSEC and HGSOC. (f) ELISA experiments showing the effects of PAX8 or SOX17 knockdown on levels of SERPINE1 in HGSOC.

Techniques: Produced, Enzyme-linked Immunosorbent Assay, Quantitation Assay

PAX8 and SOX17 regulate the secretion of angiogenesis mediators. (a) Human angiogenesis arrays of fresh DMEM/F12 and RMPI media with no detection of angiogenesis mediators, negative controls. (b-c-d) Human angiogenesis array of additional three fallopian tube secretory cells and additional three ovarian carcinoma cells conditioned media after PAX8 or SOX17 knockdown.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8 and SOX17 regulate the secretion of angiogenesis mediators. (a) Human angiogenesis arrays of fresh DMEM/F12 and RMPI media with no detection of angiogenesis mediators, negative controls. (b-c-d) Human angiogenesis array of additional three fallopian tube secretory cells and additional three ovarian carcinoma cells conditioned media after PAX8 or SOX17 knockdown.

Techniques:

PAX8 and SOX17 promote ovarian cancer angiogenesis. (a) Endothelial cells tube formation assay. Representative images depict negative control, VEGF, SERPINE1, FTSEC, and HGSOC conditioned media after PAX8 or SOX17 knockdown. (b) Quantitation of the HUVEC neo-vessels loops. (c) Neovascularization in angioreactors containing conditioned media from HGSOC cells, but not from FTSEC after implantation in nude mice. (d) Quantitation of endothelial cell invasion into angioreactors.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8 and SOX17 promote ovarian cancer angiogenesis. (a) Endothelial cells tube formation assay. Representative images depict negative control, VEGF, SERPINE1, FTSEC, and HGSOC conditioned media after PAX8 or SOX17 knockdown. (b) Quantitation of the HUVEC neo-vessels loops. (c) Neovascularization in angioreactors containing conditioned media from HGSOC cells, but not from FTSEC after implantation in nude mice. (d) Quantitation of endothelial cell invasion into angioreactors.

Techniques: Tube Formation Assay, Negative Control, Quantitation Assay

PAX8-SOX17 regulates angiogenesis through the PLCy1 pathway. (a) Schematic illustration of the PLCy1 pathway. (b) RPPA analysis showing up-regulation of VEGFR2 protein levels followed PAX8 and SOX17 knockdown. (c) RPPA analysis showing reduced phosphorylated-PLCy1 and phosphorylated-ERK1/2 (active molecules) followed PAX8 and SOX17 knockdown. (d) Confirmation by western blot of the PLCy1 pathway inactivation.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8-SOX17 regulates angiogenesis through the PLCy1 pathway. (a) Schematic illustration of the PLCy1 pathway. (b) RPPA analysis showing up-regulation of VEGFR2 protein levels followed PAX8 and SOX17 knockdown. (c) RPPA analysis showing reduced phosphorylated-PLCy1 and phosphorylated-ERK1/2 (active molecules) followed PAX8 and SOX17 knockdown. (d) Confirmation by western blot of the PLCy1 pathway inactivation.

Techniques: Western Blot

PAX8 or SOX17 doxycycline-inducible knockdown inhibits ovarian cancer progression. (a) Immunoblot of OVTOKO cells harboring inducible shPAX8 or shSOX17 before and after the induction with 1μg/ml of doxycycline. (b) In vivo imaging of OVTOKO tumors in NSG female mice. Animals were imaged after two weeks of doxycycline supplementation. (c) Necropsy of animals depicting ascites and tumors (white arrow) only in the non-targeting control group. (d) The volume of ascites collected from mice after two weeks of doxycycline supplementation. (e) NSG mice reproductive system depicting ovarian cancer volume.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8 or SOX17 doxycycline-inducible knockdown inhibits ovarian cancer progression. (a) Immunoblot of OVTOKO cells harboring inducible shPAX8 or shSOX17 before and after the induction with 1μg/ml of doxycycline. (b) In vivo imaging of OVTOKO tumors in NSG female mice. Animals were imaged after two weeks of doxycycline supplementation. (c) Necropsy of animals depicting ascites and tumors (white arrow) only in the non-targeting control group. (d) The volume of ascites collected from mice after two weeks of doxycycline supplementation. (e) NSG mice reproductive system depicting ovarian cancer volume.

Techniques: Western Blot, In Vivo Imaging

PAX8-SOX17 suppress anti-angiogenesis factors. (a) Spearman correlation analysis of TCGA ovarian cancer data set depicting negative inversely correlation between SOX17 and angiogenesis inhibitors (SERPINE1 and THBS1). (b) Schematic diagram of the activation of tumor angiogenesis by PAX8 and SOX17 expression.

Journal: bioRxiv

Article Title: PAX8 orchestrates an angiogenic program through interaction with SOX17

doi: 10.1101/2020.09.09.290387

Figure Lengend Snippet: PAX8-SOX17 suppress anti-angiogenesis factors. (a) Spearman correlation analysis of TCGA ovarian cancer data set depicting negative inversely correlation between SOX17 and angiogenesis inhibitors (SERPINE1 and THBS1). (b) Schematic diagram of the activation of tumor angiogenesis by PAX8 and SOX17 expression.

Techniques: Activation Assay, Expressing

array buffer 1 Search Results

Image Search Results